The study, led by Dr Lucy Vivash, was published in the journal Alzheimer’s and Dementia: Translational Research and Clinical Interventions.
According to Dr Vivash, sodium selenate upregulates an enzyme in the brain that effectively breaks down the tau protein.
She said: “We have previously shown, in a Phase 2 trial, that sodium selenate given to patients with mild to moderate Alzheimer’s Disease resulted in less neurodegeneration than in those who did not.”
The patients with higher levels of selenium, a breakdown product of sodium selenate, in their blood showed less cognitive decline during the trial.
if(typeof utag_data.ads.fb_pixel!==”undefined”&&utag_data.ads.fb_pixel==!0){!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function(){n.callMethod?n.callMethod.apply(n,arguments):n.queue.push(arguments)};if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version=’2.0′;n.queue=[];t=b.createElement(e);t.async=!0;t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,document,’script’,’https://connect.facebook.net/en_US/fbevents.js’);fbq(‘init’,’568781449942811′);fbq(‘track’,’PageView’)}
